Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 4/2019

01-08-2019 | Research Article

Pharmacotherapy related quality of life in Thai patients with chronic diseases

Author: Phantipa Sakthong

Published in: International Journal of Clinical Pharmacy | Issue 4/2019

Login to get access

Abstract

Background Little was known about patient’s pharmacotherapy related quality of life (PTRQoL) and its differences between disease groups. Objective First, to assess PTRQoL in Thai patients with chronic diseases using the Patient-Reported Outcomes Measure of Pharmaceutical Therapy for Quality of Life (PROMPT-QoL). Second, to determine the differences in PROMPT-QoL domain scores and total scores between disease groups. Setting Three public university hospitals in Bangkok, Thailand. Method Eleven hundred and fifty-six adult outpatients continuously taking medicines to treat their diseases for at least 3 months were conveniently sampled. Bonferroni post hoc tests were used to determine the differences in eight PROMPT-QoL domain scores and total scores between 14 disease groups. Main outcome measure The descriptive statistics of PROMPT-QoL domains and the total score. Results Approximately two-thirds of all patients preferred to use only medicines for treating their diseases. Impacts of Medicines and Side-Effects and Medicine and Disease Information yielded the highest (87.3) and lowest (55.4) mean domain scores, respectively. The other domains and the total score provided the average scores between 65 and 75, which were interpreted as moderate-to-good. Bonferroni post hoc tests showed that there were five domains providing significantly different scores between disease groups. They included Medicine and Disease Information, Satisfaction with Medicine Effectiveness, Impacts of Medicines and Side-effects, Convenience, and Therapeutic Relationships with Healthcare Providers domains. Conclusion Pharmacotherapy related quality of life in Thai patients is moderate-to-good. Five of eight pharmacotherapy related quality of life domain scores differed by disease groups.
Literature
1.
go back to reference Institute of Medicine. Crossing the quality chasm: a new health system for the 21st century. Washington, DC: National Academy Press; 2001. ISBN-10 0-309-07280-8. Institute of Medicine. Crossing the quality chasm: a new health system for the 21st century. Washington, DC: National Academy Press; 2001. ISBN-10 0-309-07280-8.
2.
go back to reference Stewart M, Brown JB, Weston WW, McWhinney IR, McWilliam CL, Freeman TR. Patient-centered medicine: transforming the clinical method. Thousand Oaks, CA: SAGE Publications; 2003. ISBN-13 978-1857759815. Stewart M, Brown JB, Weston WW, McWhinney IR, McWilliam CL, Freeman TR. Patient-centered medicine: transforming the clinical method. Thousand Oaks, CA: SAGE Publications; 2003. ISBN-13 978-1857759815.
3.
go back to reference Lohr KN, Zebrack BL. Using patient-reported outcomes in clinical practice: challenges and opportunities. Qual Life Res. 2009;18:99–107.CrossRefPubMed Lohr KN, Zebrack BL. Using patient-reported outcomes in clinical practice: challenges and opportunities. Qual Life Res. 2009;18:99–107.CrossRefPubMed
4.
go back to reference Bungay KM, Boyer JG, Steinwald AB, Ware JE. Health-related quality of life: an overview. In: Bootman JL, Townsend RJ, McGhan WF, editors. Principle of pharmacoeconomics. 2nd ed. Cincinnati, OH: Wharvey Whitney Books Company; 1996. p. 128–48. ISBN 0-929375-17-3. Bungay KM, Boyer JG, Steinwald AB, Ware JE. Health-related quality of life: an overview. In: Bootman JL, Townsend RJ, McGhan WF, editors. Principle of pharmacoeconomics. 2nd ed. Cincinnati, OH: Wharvey Whitney Books Company; 1996. p. 128–48. ISBN 0-929375-17-3.
5.
go back to reference Murawski MM, Bentley JP. Pharmaceutical therapy-related quality of life: conceptual development. J Soc Admin Pharm. 2001;18:2–14. Murawski MM, Bentley JP. Pharmaceutical therapy-related quality of life: conceptual development. J Soc Admin Pharm. 2001;18:2–14.
6.
go back to reference Ernst FR, Grizzel AJ. Drug-related morbidity and mortality updating the cost-of-illness model. J Am Pharm Assoc. 2001;41:192–9. Ernst FR, Grizzel AJ. Drug-related morbidity and mortality updating the cost-of-illness model. J Am Pharm Assoc. 2001;41:192–9.
7.
go back to reference Sakthong P, Suksanga P, Sakulbumrungsil R, Winit-Watjana W. Development of Patient-Reported Outcomes Measure of Pharmaceutical Therapy for Quality of Life (PROMPT-QoL): a novel instrument for medication management. Res Soc Admin Pharm. 2015;11:315–38.CrossRef Sakthong P, Suksanga P, Sakulbumrungsil R, Winit-Watjana W. Development of Patient-Reported Outcomes Measure of Pharmaceutical Therapy for Quality of Life (PROMPT-QoL): a novel instrument for medication management. Res Soc Admin Pharm. 2015;11:315–38.CrossRef
8.
go back to reference Cipolle RJ, Strand LM, Morley PC, editors. Pharmaceutical care practice: the clinician’s guide. 2nd ed. New York: McGraw-Hill; 2004. ISBN 0-07-136259-2. Cipolle RJ, Strand LM, Morley PC, editors. Pharmaceutical care practice: the clinician’s guide. 2nd ed. New York: McGraw-Hill; 2004. ISBN 0-07-136259-2.
9.
go back to reference WHOQOL Group. The development of the World Health Organization Quality of Life Assessment Instrument (the WHOQOL). In: Orley J, Kunyken W, editors. Quality of life assessment: international perspectives. Springer-Verlag: Berlin; 1994. p. 40. ISBN 978-3-642-79123-9. WHOQOL Group. The development of the World Health Organization Quality of Life Assessment Instrument (the WHOQOL). In: Orley J, Kunyken W, editors. Quality of life assessment: international perspectives. Springer-Verlag: Berlin; 1994. p. 40. ISBN 978-3-642-79123-9.
10.
go back to reference Campbell A, Converse P, Rogers WL. The quality of American life: perceptions, evaluations and satisfactions. New York: Russell Sage; 1976. p. 23–59. ISBN 87154-194-7. Campbell A, Converse P, Rogers WL. The quality of American life: perceptions, evaluations and satisfactions. New York: Russell Sage; 1976. p. 23–59. ISBN 87154-194-7.
11.
go back to reference Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. JAMA. 1995;273:59–65.CrossRef Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. JAMA. 1995;273:59–65.CrossRef
12.
go back to reference Sakthong P, Chinthammit C, Sukarnjanaset P, Sonsa-ardjit N, Munpan W. Psychometric properties of the Patient-Reported Outcomes Measure of Pharmaceutical Therapy for Quality of Life (PROMPT-QoL). Value Health RI. 2017;12C:41–9.CrossRef Sakthong P, Chinthammit C, Sukarnjanaset P, Sonsa-ardjit N, Munpan W. Psychometric properties of the Patient-Reported Outcomes Measure of Pharmaceutical Therapy for Quality of Life (PROMPT-QoL). Value Health RI. 2017;12C:41–9.CrossRef
13.
go back to reference Sakthong P, Sangthonganotai T. A randomized controlled trial of the impact of pharmacist-led patient-centered pharmaceutical care on patients’ medicine therapy-related quality of life. Res Soc Admin Pharm. 2018;14:332–9.CrossRef Sakthong P, Sangthonganotai T. A randomized controlled trial of the impact of pharmacist-led patient-centered pharmaceutical care on patients’ medicine therapy-related quality of life. Res Soc Admin Pharm. 2018;14:332–9.CrossRef
14.
go back to reference Krska J, Katusiime B, Corlett SA. Validation of an instrument to measure patients’ experiences of medicine use: the living with medicines questionnaire. Patient Prefer Adherence. 2017;11:671–9.CrossRefPubMedPubMedCentral Krska J, Katusiime B, Corlett SA. Validation of an instrument to measure patients’ experiences of medicine use: the living with medicines questionnaire. Patient Prefer Adherence. 2017;11:671–9.CrossRefPubMedPubMedCentral
15.
go back to reference Tseng HM, Lee CH, Chen YJ, Hsu HH, Huang LY, Huang JL. Developing a measure of medication-related quality of life for people with polypharmacy. Qual Life Res. 2016;25:1295.CrossRefPubMed Tseng HM, Lee CH, Chen YJ, Hsu HH, Huang LY, Huang JL. Developing a measure of medication-related quality of life for people with polypharmacy. Qual Life Res. 2016;25:1295.CrossRefPubMed
17.
go back to reference Sakthong P, Winit-Watjana W, Sakulbumrungsil R. Understanding the medication experiences of Thai patients attending a medication therapy management clinic. Thai J Pharm Sci. 2014;38:21–7. Sakthong P, Winit-Watjana W, Sakulbumrungsil R. Understanding the medication experiences of Thai patients attending a medication therapy management clinic. Thai J Pharm Sci. 2014;38:21–7.
18.
go back to reference Sakthong P, Sakulbumrungsil R, Winit-Watjana W. Medication-therapy-related quality of life measurement using the patient-generated index: a pilot study. Int J Pharm Pharm Sci. 2013;5:153–6. Sakthong P, Sakulbumrungsil R, Winit-Watjana W. Medication-therapy-related quality of life measurement using the patient-generated index: a pilot study. Int J Pharm Pharm Sci. 2013;5:153–6.
20.
go back to reference Choowong J, Tillgren P, Söderbäck M. Thai people living with tuberculosis and how they adhere to treatment: a grounded theory study. Nurs Health Sci. 2017;19:436–43.CrossRefPubMed Choowong J, Tillgren P, Söderbäck M. Thai people living with tuberculosis and how they adhere to treatment: a grounded theory study. Nurs Health Sci. 2017;19:436–43.CrossRefPubMed
21.
go back to reference Patsuree A, Krska J, Jarernsiripornkula N. Experiences relating to adverse drug reactions in the community: a cross-sectional survey among patients and the general public in Thailand. Expert Opin Drug Saf. 2016;15:287–95.CrossRefPubMed Patsuree A, Krska J, Jarernsiripornkula N. Experiences relating to adverse drug reactions in the community: a cross-sectional survey among patients and the general public in Thailand. Expert Opin Drug Saf. 2016;15:287–95.CrossRefPubMed
22.
go back to reference Saengcharoen W, Buasri N, Khantapokha B, Lerkiatbundit S. Public knowledge and factors associated with inappropriate analgesic use: a survey in Thailand. IJPP. 2016;24:22–9. Saengcharoen W, Buasri N, Khantapokha B, Lerkiatbundit S. Public knowledge and factors associated with inappropriate analgesic use: a survey in Thailand. IJPP. 2016;24:22–9.
24.
go back to reference Nabeela AS, Abdulkareem A, Abdulhakeem A, Salah LQ, Heba M. Depressed patients’ preferences for education about medications by pharmacists in Kuwait. Patient Educ Couns. 2008;72:94–101.CrossRef Nabeela AS, Abdulkareem A, Abdulhakeem A, Salah LQ, Heba M. Depressed patients’ preferences for education about medications by pharmacists in Kuwait. Patient Educ Couns. 2008;72:94–101.CrossRef
25.
go back to reference Medina PJ, Shord SS. Cancer treatment ad chemotherapy. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey ML, editors. Pharmacotherapy: a pathophysiologic approach. 8th ed. New York: McGraw-Hill; 2011. p. 2191–227. Medina PJ, Shord SS. Cancer treatment ad chemotherapy. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey ML, editors. Pharmacotherapy: a pathophysiologic approach. 8th ed. New York: McGraw-Hill; 2011. p. 2191–227.
27.
go back to reference Balayssac D, Ferrier J, Descoeur J, Ling B, Pezet D, Eschalier A, et al. Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. Expert Opin Drug Saf. 2011;10:407–17.CrossRefPubMed Balayssac D, Ferrier J, Descoeur J, Ling B, Pezet D, Eschalier A, et al. Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. Expert Opin Drug Saf. 2011;10:407–17.CrossRefPubMed
28.
go back to reference Rouanne M, Massard C, Hollebecque A, Rousseau V, Varga A, Gazzah A, et al. Evaluation of sexuality, health-related quality-of-life and depression in advanced cancer patients: a prospective study in a Phase I clinical trial unit of predominantly targeted anticancer drugs. Eur J Cancer. 2013;49:431–8.CrossRefPubMed Rouanne M, Massard C, Hollebecque A, Rousseau V, Varga A, Gazzah A, et al. Evaluation of sexuality, health-related quality-of-life and depression in advanced cancer patients: a prospective study in a Phase I clinical trial unit of predominantly targeted anticancer drugs. Eur J Cancer. 2013;49:431–8.CrossRefPubMed
29.
go back to reference Matzke GR. Renal disorders. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey ML, editors. Pharmacotherapy: a pathophysiologic approach. 8th ed. New York: McGraw-Hill; 2011. p. 719–942. Matzke GR. Renal disorders. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey ML, editors. Pharmacotherapy: a pathophysiologic approach. 8th ed. New York: McGraw-Hill; 2011. p. 719–942.
30.
go back to reference Offurum A, Wagner LA, Gooden T. Adverse safety events in patients with Chronic Kidney Disease (CKD). Expert Opin Drug Saf. 2016;15:1597–607.CrossRefPubMed Offurum A, Wagner LA, Gooden T. Adverse safety events in patients with Chronic Kidney Disease (CKD). Expert Opin Drug Saf. 2016;15:1597–607.CrossRefPubMed
31.
go back to reference Chakraborty S, Ghosh S, Banerjea A, De RR, Hazra A, Mandal SK. Prescribing patterns of medicines in chronic kidney disease patients on maintenance hemodialysis. Indian J Pharmacol. 2016;48:586–90.CrossRefPubMedPubMedCentral Chakraborty S, Ghosh S, Banerjea A, De RR, Hazra A, Mandal SK. Prescribing patterns of medicines in chronic kidney disease patients on maintenance hemodialysis. Indian J Pharmacol. 2016;48:586–90.CrossRefPubMedPubMedCentral
32.
go back to reference Raichani LE, Du Q, Mathieu A, Almassy S, Lalonde L, Berbiche D, et al. Development and validation of PART (Pharmacotherapy Assessment in Renal Transplant Patients) criteria to assess drug-related problems in an outpatient renal transplant population: a cross-sectional study. Pharmacol Res Perspect. 2019;15(7):e00453. https://doi.org/10.1002/prp2.453.CrossRef Raichani LE, Du Q, Mathieu A, Almassy S, Lalonde L, Berbiche D, et al. Development and validation of PART (Pharmacotherapy Assessment in Renal Transplant Patients) criteria to assess drug-related problems in an outpatient renal transplant population: a cross-sectional study. Pharmacol Res Perspect. 2019;15(7):e00453. https://​doi.​org/​10.​1002/​prp2.​453.CrossRef
33.
go back to reference Sarkis RA, Goksen Y, Mu Y, Rosner B, Lee JW. Cognitive and fatigue side effects of anti-epileptic drugs: an analysis of phase III add-on trials. J Neurol. 2018;265:2137–42.CrossRefPubMed Sarkis RA, Goksen Y, Mu Y, Rosner B, Lee JW. Cognitive and fatigue side effects of anti-epileptic drugs: an analysis of phase III add-on trials. J Neurol. 2018;265:2137–42.CrossRefPubMed
34.
go back to reference Borovac JA. Side effects of a dopamine agonist therapy for Parkinson’s disease: a mini-review of clinical pharmacology. Yale J Biol Med. 2016;89:37–47.PubMedPubMedCentral Borovac JA. Side effects of a dopamine agonist therapy for Parkinson’s disease: a mini-review of clinical pharmacology. Yale J Biol Med. 2016;89:37–47.PubMedPubMedCentral
35.
go back to reference Krska J, Katusiime B, Corlett SA. Complexity of medicine regimens and patient perceptions of medicine burden. Pharmacy. 2019;7:18.CrossRef Krska J, Katusiime B, Corlett SA. Complexity of medicine regimens and patient perceptions of medicine burden. Pharmacy. 2019;7:18.CrossRef
37.
go back to reference Van Camp YP, Vrijens B, Abraham I, Van Rompaey B, Elseviers MM. Adherence to phosphate binders in hemodialysis patients: prevalence and determinants. J Nephrol. 2014;27:673–9.CrossRefPubMed Van Camp YP, Vrijens B, Abraham I, Van Rompaey B, Elseviers MM. Adherence to phosphate binders in hemodialysis patients: prevalence and determinants. J Nephrol. 2014;27:673–9.CrossRefPubMed
38.
go back to reference Phuphanich M, Rattanamahattana M, Avihingsanon A, Chetchotisakd P, Putcharoen O, Gandhi M, et al. A qualitative assessment of barriers and facilitators to antiretroviral adherence in Thai patients. J Virus Erad. 2016;2:22–7.PubMedPubMedCentral Phuphanich M, Rattanamahattana M, Avihingsanon A, Chetchotisakd P, Putcharoen O, Gandhi M, et al. A qualitative assessment of barriers and facilitators to antiretroviral adherence in Thai patients. J Virus Erad. 2016;2:22–7.PubMedPubMedCentral
Metadata
Title
Pharmacotherapy related quality of life in Thai patients with chronic diseases
Author
Phantipa Sakthong
Publication date
01-08-2019
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 4/2019
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-019-00857-9

Other articles of this Issue 4/2019

International Journal of Clinical Pharmacy 4/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.